|Bid||3.8000 x 800|
|Ask||4.3000 x 1100|
|Day's Range||3.8000 - 4.1200|
|52 Week Range||3.6600 - 19.3900|
|Beta (5Y Monthly)||1.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2022 - Nov 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.39|
Subscribe to Yahoo Finance Plus to view Fair Value for DRIO
DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today new research examining the link between the use of Dario's biofeedback device to help users improve their posture and reduced back pain at the International Association of the Study of Pain (IASP) 2022 World Congress on Pain, being held in person in Toronto, Ontario from September 19th – 23rd and virtually.
DarioHealth Corp. (NASDAQ: DRIO) (the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today two new employer contracts, including one for the full suite of integrated solutions. The new accounts are scheduled to launch in late 2022 and early 2023.
By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT Second Quarter 2022 Financial and Operational Results On August 15, 2022, DarioHealth Corp. (NASDAQ:DRIO) published its second quarter 2022 operational and financial results in a press release and filed its Form 10-Q for the three-month period ending June 30, 2022. Dario hosted a conference call and webcast to discuss